TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC

Triple-negative breast cancer (TNBC) is a heterogeneous and aggressive type of breast cancer with a poor prognosis and a high recurrence rate. Chemotherapy is still the mainstay of treatment for cancer patients without a genetic BRCA mutation, despite the approval of Olaparib, an inhibitor of the po...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ning, Li, Peng, Sun, Xiaolin, Tong, Li, Dong, Xinyi, Zhang, Xuemei, Duan, Jifeng, Sheng, Xia, Xin, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589312/
https://www.ncbi.nlm.nih.gov/pubmed/37864041
http://dx.doi.org/10.1038/s41523-023-00588-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589312/
https://www.ncbi.nlm.nih.gov/pubmed/37864041
http://dx.doi.org/10.1038/s41523-023-00588-1

Ejemplares similares